NINGBO INNO PHARMCHEM CO.,LTD. is proud to highlight a critical component in the pharmaceutical manufacturing landscape: 3,4-dihydro-7-methoxy-4-oxoquinazolin-6-yl acetate. This compound, identified by CAS number 179688-53-0, serves as an indispensable intermediate in the production of Gefitinib, a vital medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). The precise synthesis and high purity of this Gefitinib synthesis intermediate are paramount for ensuring the efficacy and safety of the final therapeutic product.

The chemical name, 3,4-dihydro-7-methoxy-4-oxoquinazolin-6-yl acetate, along with its molecular formula C11H10N2O4 and molecular weight of 234.20800, defines its unique chemical identity. Available as an off-white to grey to brownish grey powder, this intermediate boasts a purity of ≥98.0% as determined by HPLC. This high level of purity is not merely a specification; it's a cornerstone for reliable pharmaceutical intermediate manufacturing, ensuring consistent performance in complex chemical reactions. The physical and chemical properties, including a melting point of 26°C and a flash point of 227.398°C, are crucial data points for safe handling, storage, and processing within industrial settings. Understanding these attributes is essential for those involved in Gefitinib production raw materials.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting the pharmaceutical industry by providing high-quality Gefitinib synthesis intermediates. Our focus on quality control for chemical intermediates ensures that manufacturers can proceed with confidence, knowing they are using materials that meet stringent industry standards. The effective use of such intermediates directly impacts the efficiency and cost-effectiveness of the overall drug manufacturing process. For companies looking to secure reliable Gefitinib production raw materials, NINGBO INNO PHARMCHEM CO.,LTD. offers a dependable source, contributing to the stable supply chain necessary for critical medications.

In the intricate world of pharmaceutical synthesis, the role of each intermediate cannot be overstated. 3,4-dihydro-7-methoxy-4-oxoquinazolin-6-yl acetate exemplifies the specialized nature of fine chemicals required for advanced drug development. Its availability and consistent quality empower researchers and manufacturers alike to push the boundaries of medical treatment. We emphasize the importance of sourcing high-purity Gefitinib intermediate to maintain the integrity of the final Gefitinib product, underscoring our dedication to supporting healthcare advancements.